Author: jauca

31 Jul Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents

Posted at 00:00h in PharmacoEpidemiology 0 Comments

Share

Schneeweiss S, Dormuth C, Grootendorst P, Soumerai SB, Maclure M Link to publication...

Read More

30 Jun [52] Antidepressant Medications in Children and Adolescents

Posted at 00:00h in Therapeutics Letter 1 Comment

Share

Regulatory Status No antidepressants are approved in Canada for individuals less than 19 years of age. In the United States, fluoxetine is approved for major depressive disorder (MDD) in individuals aged 8 years and older. However,...

Read More

17 May Better Prescribing Project: a randomized controlled trial of the impact of case-based educational modules and personal prescribing feedback on prescribing for hypertension in primary care

Posted at 23:56h in PharmacoEpidemiology 0 Comments

Share

Herbert CP, Wright JM, Maclure M, Wakefield J, Dormuth C, Brett-MacLean P, Legare J, Premi J Link to publication...

Read More

31 Mar [51] New Drugs VIII – Telithromycin (Ketek®), Ezetimibe (Ezetrol®), Topical Pimecrolimus (Elidel®), and Tacrolimus (Protopic®)

Posted at 00:00h in Therapeutics Letter 0 Comments

Share

Telithromycin (Ketek®) Ezetimibe (Ezetrol®) Topical Pimecrolimus (Elidel®) and Tacrolimus (Protopic®) References Telithromycin (Ketek®) Approved indications: Community-acquired pneumonia (mild to moderate) (CAP), acute bacterial exacerbation of chronic bronchitis (AECB), and tonsillitis/pharyngitis (patients intolerant to beta-lactam antibiotics). Mechanism of action:  Telithromycin is...

Read More